CrushSCI.com
96.2Average days
80Median days
31Fastest days
205Longest days
712025 publications

Paper Review Records

All Paper Review Records

20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

83 days

Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis

Authors
Akihiro Matsukawa; Keiichiro Mori; Takafumi Yanagisawa; Keiichiro Miyajima; Yuki Enei; Wataru Fukuokaya; Kagenori Ito; Shunsuke Tsuzuki; Angelo Cormio; Marcin Miszczyk; Benjamin Pradere; Marco Moschini; Shahrokh F. Shariat; Jun Miki; Takahiro KimuraShow moreShow less
Affiliations
1. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; 2. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 3. Department of Urology, Università Politecnica Delle Marche, Ancona, Italy; 4. Collegium Medicum—Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland; 5. Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France; 6. Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffael, Milan, Italy; 7. Department of Urology, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran; 8. Department of Urology, Semmelweis University, Budapest, Hungary; 9. Department of Urology, The University of Texas Southwestern Medical Center, Dallas, USA; 10. Department of Urology, Weill Cornell Medical College, New York, USA; 11. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; 12. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; 13. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; 14. Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, IranShow moreShow less
Source PDF DOI Publisher page
36 days

Beyond Tumor-Agnostic TMB: Histology-Dependent Efficacy and Clinical Interpretation of Immune Checkpoint Inhibitors in TMB-High Solid Tumors

Authors
Tamotsu Sagawa; Masahiro Hirakawa; Hiroyuki Nagashima; Koshi FujikawaShow moreShow less
Affiliations
1. Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; 2. Division of Medical Oncology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, JapanShow moreShow less
Source PDF DOI Publisher page
52 days

Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review

Authors
Nadav Harel; Anthony Hamilton; Thomas C. T. Cope; William Harris; Yael Lefkovits; Mark Middleton; Jayesh Desai; Jeanne TieShow moreShow less
Affiliations
1. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; 2. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; 3. The Royal Melbourne Hospital, Melbourne, Australia; 4. Auckland City Hospital, Auckland, New Zealand; 5. Cabrini Health, Melbourne, Australia; 6. Department of Oncology, University of Oxford, Oxford, UK; 7. Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, AustraliaShow moreShow less
Source PDF DOI Publisher page
171 days

Clinical Significance of Comprehensive Genomic Profiling According to RAS and BRAF Status in Metastatic Colorectal Cancer

Authors
Kazuki Ogawa; Hiroyuki Arai; Yuka Makino; Yohei Kubota; Yusuke Nagata; Yoshiki Horie; Hiroyuki Takeda; Kumiko Umemoto; Naoki Izawa; Yoshiaki Nakamura; Takayuki Yoshino; Yu SunakawaShow moreShow less
Affiliations
1. Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki-shi, Japan; 2. Translational Research Support Office, National Cancer Center, Hospital East, Kashiwa, Japan; 3. Department of Oncology, University of Oxford, Oxford, UK; 4. Department of Gastrointestinal Oncology, National Cancer Center, Hospital East, Kashiwa, JapanShow moreShow less
Source PDF DOI Publisher page
138 days

Imlunestrant as Monotherapy or in Combination with Abemaciclib in ER+, HER2− Advanced Breast Cancer: Chinese Subgroup Analysis of the Phase III Randomized EMBER-3 Study

Authors
Xiaojia Wang; Jingwei Xu; Zhongsheng Tong; Tao Wu; Quchang Ouyang; Jian Liu; Yanxia Shi; Juan Huang; Hao Wang; Xinshuai Wang; Huihua Xiong; Jingjing Li; Li Zhou; Wanli Zhang; Qingyuan ZhangShow moreShow less
Affiliations
1. Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China; 2. Department of Breast Surgery, The Second Hospital of Jilin University, Changchun, China; 3. Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 4. Department of Oncology, Changde Hospital Affiliated to Xiangya School of Medicine, Central South University, The First People’s Hospital of Changde City, Changde, China; 5. Department of Breast Internal Medicine, Hunan Cancer Hospital, Changsha, China; 6. Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China; 7. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; 8. Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China; 9. Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China; 10. Department of Medical Oncology, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China; 11. Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; 12. Eli Lilly and Company, Shanghai, China; 13. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, ChinaShow moreShow less
Source PDF DOI Publisher page
41 days

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Authors
Veronique Dieras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; Giovanna Granata; Qi Shen; Erika HamiltonShow moreShow less
Affiliations
1. Medical Oncology Department, Centre Eugène Marquis, Rennes, France; 2. European Institute of Oncology, IRCCS, Milan, Italy; 3. Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; 4. Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain; 5. Institut Curie, Paris, France; 6. The Innovative Center of Translational Research and Clinical Science for Cancer Therapy, Showa Medical University Hospital, Tokyo, Japan; 7. Department of Medicine, The Ottawa Hospital Cancer Centre, Ottawa, Canada; 8. Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada; 9. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 10. Department of Medical Oncology, Mayo Clinic, Rochester, USA; 11. Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 12. Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; 13. Institute of Cancer Research, London, UK; 14. Breast Care Center, National Taiwan University Hospital, Taipei, Taiwan; 15. Département d’Oncologie Médicale, Institut Regional du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France; 16. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea; 17. Medical Oncology, Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Brazil; 18. Department of Gynecology and University Breast Center, Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany; 19. Biostatistics, Pfizer Inc., Bothell, USA; 20. Oncology Late Stage Development, Pfizer AG, Zug, Switzerland; 21. Oncology, Research and Development, Pfizer Inc, Collegeville, USA; 22. Medical Oncology, Sarah Cannon Research Institute, Nashville, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Targeted Oncology take to review a manuscript?

As of 2026-11-18, CrushSCI has 20 complete review records for Targeted Oncology. The fastest paper went from submission to acceptance in 31 days (Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?, received 2026-04-20, accepted 2026-05-21); the slowest took 205 days. The average is 96.2 days and the median is 80 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.